Fecal Transplant Fails to Decolonize Resistant Bacteria in GI Disease

The human gut serves as a critical reservoir for antimicrobial resistance genes, where dysbiosis (a pathological imbalance in microbial composition and function) often facilitates the proliferation of multidrug-resistant organisms [1, 2]. For patients with chronic gastrointestinal conditions, this colonization significantly increases the risk of invasive infections, healthcare-associated transmission, and overall mortality [3, 4]. While fecal microbiota transplantation (the transfer of screened donor stool into a recipient's gastrointestinal tract to restore microbial ecology) has become a standard intervention for recurrent Clostridioides difficile infection, its utility in eradicating other resistant pathogens remains a subject of active clinical investigation [5, 6, 7]. Current evidence regarding the efficacy of microbial restoration for decolonization is inconsistent, as meta-analyses of randomized trials have shown no significant effect on short-term (RR=1.18; 95% CI 0.81-1.71) or long-term decolonization rates [3, 8]. A recent randomized, sham-controlled trial involving 114 patients now provides rigorous data on whether this approach can effectively clear resistant strains in high-risk populations [9].